Sharon A Riddler

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity
    Sharon A Riddler
    University of Pittsburgh, Pennsylvania, USA
    Antimicrob Agents Chemother 46:3877-82. 2002
  2. ncbi Impact of HIV infection and HAART on serum lipids in men
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 289:2978-82. 2003
  3. ncbi Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Acquir Immune Defic Syndr 48:281-8. 2008
  4. ncbi Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
  5. ncbi Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
    Theresa L Whiteside
    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Vaccine Immunol 16:233-40. 2009
  6. ncbi Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
    Nancy C Connolly
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Vaccine Immunol 15:284-92. 2008
  7. ncbi Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART
    Bernard J C Macatangay
    Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 5:e9852. 2010
  8. ncbi A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
  9. ncbi Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase
    Jessica H Brehm
    Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    J Acquir Immune Defic Syndr 56:344-8. 2011
  10. ncbi Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches
    Nancy C Connolly
    University of Pittsburgh, Pittsburgh, PA 15213, USA
    AIDS Rev 7:168-80. 2005

Detail Information

Publications20

  1. ncbi Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity
    Sharon A Riddler
    University of Pittsburgh, Pennsylvania, USA
    Antimicrob Agents Chemother 46:3877-82. 2002
    ..The combination of IDV and NFV was generally well tolerated and resulted in sustained virologic suppression with 45% of the subjects having an HIV-1 RNA level in plasma of <400 copies/ml at week 72 (intent-to-treat)...
  2. ncbi Impact of HIV infection and HAART on serum lipids in men
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 289:2978-82. 2003
    ....
  3. ncbi Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Acquir Immune Defic Syndr 48:281-8. 2008
    ..Alterations in serum lipids and an increased risk of myocardial infarction have been associated with HIV-1 infection and its treatment...
  4. ncbi Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
    ..The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs...
  5. ncbi Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
    Theresa L Whiteside
    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Vaccine Immunol 16:233-40. 2009
    ..bb-ind-13137)...
  6. ncbi Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
    Nancy C Connolly
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Vaccine Immunol 15:284-92. 2008
    ..DC vaccination was safe, was feasible, and showed promise of immunogenicity in ART-treated, HIV-1-positive individuals. Additional studies of DC immunization strategies for HIV-1 infection are warranted...
  7. ncbi Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART
    Bernard J C Macatangay
    Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 5:e9852. 2010
    ..The Treg suppressive effect masked an increase in the vaccine-induced anti-HIV-1-specific polyfunctional response. The role of Treg should be considered in immunotherapeutic trials of HIV-1 infection...
  8. ncbi A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
    ..Clinical stability has been observed with continued antiretroviral therapy (ART) in the setting of partial virological suppression. The optimal time to switch treatment in patients with low but detectable HIV-1 RNA is not known...
  9. ncbi Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase
    Jessica H Brehm
    Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    J Acquir Immune Defic Syndr 56:344-8. 2011
    ..001; M184I/V, P = 0.016). Selection of mutations in C-terminal domains of RT is not common with early failure of efavirenz-containing regimens...
  10. ncbi Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches
    Nancy C Connolly
    University of Pittsburgh, Pittsburgh, PA 15213, USA
    AIDS Rev 7:168-80. 2005
    ..This review presents what is known about the dysregulation of proinflammatory cytokines in HIV-1 infection, highlighting newly available immune-based therapies that could augment antiretroviral drug therapies...
  11. ncbi Recovery of replication-competent HIV type 1-infected circulating monocytes from individuals receiving antiretroviral therapy
    Sharon M Harrold
    Department of Pathology, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    AIDS Res Hum Retroviruses 18:427-34. 2002
    ..These studies demonstrate that HIV-infected individuals on ART with breakthrough viremia have significantly higher levels of circulating infected monocytes, the precursors of tissue macrophages...
  12. ncbi Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Cambridge, MA 02139, USA
    J Infect Dis 195:1169-76. 2007
    ..We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based versus efavirenz (EFV)-based regimens...
  13. ncbi Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study
    Xiuhong Li
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Acquir Immune Defic Syndr 38:320-8. 2005
    ..CONCLUSIONS: Host characteristics play a role in short interruptions, whereas longer interruptions may be clinically indicated. These longer stoppages had further virologic and immunologic consequences, however...
  14. ncbi Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study
    Frank J Palella
    Northwestern University, Feinberg School of Medicine, Div of Infectious Diseases, Chicago, Illinois 60611, USA
    Clin Infect Dis 38:903-7. 2004
    ....
  15. ncbi Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men
    Bryan Lau
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    AIDS 17:2035-44. 2003
    ..These results suggest that TLC and Hgb might be useful for monitoring disease progression in resource-limited settings...
  16. ncbi Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy
    Stephen J Gange
    Department of Epidemiology and Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
    AIDS 17:119-21. 2003
  17. ncbi Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study
    Todd T Brown
    Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
    AIDS 19:1375-83. 2005
    ..To estimate insulin resistance and its relationship to antiretroviral therapy (ART) in a cohort of HIV-infected persons with comparison to HIV-seronegative controls...
  18. ncbi Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection
    Bryan Lau
    Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 39:620-5. 2005
    ..These results support the potential utility of these markers for monitoring HIV-infected people in resource-limited regions, but critical levels and rates of decline of markers for such regions remain to be defined...
  19. ncbi Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study
    Todd T Brown
    Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD, USA
    Arch Intern Med 165:1179-84. 2005
    ..The risk of diabetes mellitus (DM) in human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) has not been well defined...
  20. ncbi Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003
    Eric C Seaberg
    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    AIDS 19:953-60. 2005
    ..UO1-AI-35041: To examine the impact of HIV infection and highly active antiretroviral therapy on systolic and diastolic hypertension...